AlbionVentures
Please call us on 020 7601 1850 or contact us online
Portfolio
Haemostatix
Haemostatix is developing first-in-class clotting agents
for the treatment of bleeding or ‘haemostasis’. The
company has pioneered a new approach to the control
of bleeding that is based on a peptide that binds to
the clotting protein fibrinogen, inducing the rapid and
targeted formation of clots. This innovative technology
platform is being used to develop a pipeline of topical
and systemic products to prevent or control different
forms of bleeding.
